Pekin Hardy Strauss, Inc. Biogen Inc. Transaction History

Pekin Hardy Strauss, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$222.59 - $267.94 $3,561 - $4,287	-16 Reduced 1.87%	840 $217,000
Q3 2022 Nov 09, 2022	BUY	$194.69 - $268.46 $166,654 - $229,801	856 New	856 $229,000
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $165,867 - $208,983	-856 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$223.92 - $287.77 $27,990 - $35,971	-125 Reduced 12.74%	856 $205,000
Q3 2021 Nov 12, 2021	SELL	$282.99 - $369.05 $42,448 - $55,357	-150 Reduced 13.26%	981 $278,000
Q1 2021 May 13, 2021	SELL	$242.95 - $284.63 $8,503 - $9,962	-35 Reduced 3.0%	1,131 $316,000
Q4 2020 Feb 11, 2021	SELL	$236.26 - $355.63 $8,505 - $12,802	-36 Reduced 3.0%	1,166 $286,000
Q3 2020 Nov 12, 2020	BUY	$264.77 - $305.71 $55,866 - $64,504	211 Added 21.29%	1,202 $341,000
Q1 2020 May 11, 2020	SELL	$268.85 - $341.04 $14,786 - $18,757	-55 Reduced 5.26%	991 $314,000
Q1 2019 May 14, 2019	SELL	$216.71 - $338.96 $2,600 - $4,067	-12 Reduced 1.13%	1,046 $247,000
Q2 2018 Aug 03, 2018	BUY	$257.52 - $306.91 $26,267 - $31,304	102 Added 10.67%	1,058 $307,000
Q3 2017 Nov 03, 2017	BUY	$281.15 - $329.69 $268,779 - $315,183	956	956 $299,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Pekin Hardy Strauss, Inc., based on Form 13F filings with the SEC.

Stay updated on Pekin Hardy Strauss, Inc. with notifications on news.